CD2BP2

Across TCGA pan-cancer cohorts, CD2BP2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD2BP2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CD2BP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD2BP2 expression acts as an unfavorable survival marker.

LIHC, SKCM, and LUAD are the cancer types where CD2BP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
SKCM	OS	Median	III,IV	0.216	0.721	.001	9	view →
LUAD	OS	Median	All	0.277	0.787	.022	8	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD2BP2–LIHC (OS)

Open the LIHC breakdown →